What is CytoSMART Technologies?
CytoSMART Technologies operates at the intersection of advanced microscopy and digital biology, providing high-throughput, non-invasive live-cell analysis systems. The company's core value proposition lies in its ability to deliver real-time, automated data acquisition, which is critical for pharmaceutical research, drug screening, and academic studies in oncology and neurology. By simplifying complex cellular monitoring, CytoSMART enables researchers to achieve higher reproducibility and efficiency in their experimental workflows. Their market position is characterized by a commitment to user-friendly, cloud-connected hardware that bridges the gap between traditional laboratory equipment and modern data-driven analytics.
How much funding has CytoSMART Technologies raised?
CytoSMART Technologies has raised a total of $5.9M across 1 funding round:
Unspecified
$5.9M
Unspecified (2019): $5.9M with participation from Eindhoven Venture Capital, Holland Capital, and BOM Brabant Ventures
Key Investors in CytoSMART Technologies
Holland Capital
Holland Capital is an actively involved investment company focused on supporting the growth of SMEs in the Technology, Healthcare, and Agrifood sectors through venture, growth, and buy-out investments.
BOM Brabant Ventures
De Brabantse Ontwikkelings Maatschappij (BOM) is dedicated to catalyzing change by supporting startups and scale-ups in Brabant through investment, knowledge, and networking.
Eindhoven Venture Capital
A regional venture capital firm specializing in early-stage technology investments and fostering innovation within the Eindhoven high-tech ecosystem.
What's next for CytoSMART Technologies?
Looking ahead, the strategic deployment of the $5.9M will likely focus on enhancing the company's software-as-a-service (SaaS) capabilities and expanding its global distribution network. As the demand for automated, high-content screening tools continues to rise within the pharmaceutical industry, CytoSMART is poised to capitalize on the shift toward decentralized and remote laboratory monitoring. The company's roadmap includes the integration of advanced machine learning algorithms to further automate image analysis, thereby reducing the time-to-insight for researchers. By maintaining its focus on scalable, high-impact technology, CytoSMART is set to navigate the next phase of its growth, potentially targeting new therapeutic areas and strengthening its competitive advantage in the life sciences sector.
See full CytoSMART Technologies company page
